Source: https://www.martindale.com/washington/district-of-columbia/john-k-crisham-160099821-a/
Timestamp: 2019-04-26 11:49:42+00:00

Document:
Experience: Representative Matters: Representing Fortune 50 company in defense of complex commercial and employment class actions in state and federal courts nationwide.; Representing Fortune 50 company, at state trial and appellate court levels, in litigation challenging the constitutionality of regional transportation authority's sales-and-use tax regime.; Secured dismissal for a Fortune 50 company of a Lanham Act false-advertising lawsuit; Secured dismissal for a Fortune 50 company of a putative class-action lawsuit asserting claims under the Fair Credit Reporting Act; Representing large, privately-held federal and state government contractor in a putative class-action litigation filed in federal court.; Represented former owner of petroleum refinery in two-and-a-half week arbitration hearing concerning claims in excess of $100 million arising from alleged corrosion-related failure of buried pipe, and subsequent release of petroleum product, at refinery. Case settled on a confidential basis prior to final ruling.; Mutual Pharm. Co. v. Bartlett, 133 S. Ct. 2466 (2013): secured U.S. Supreme Court decision holding that the Hatch-Waxman Act preempts state-law tort claims targeting the design/composition of generic drug products.; PLIVA, Inc. v. Mensing, 131 S. Ct. 2567 (2011): secured U.S. Supreme Court decision holding that the Hatch-Waxman Act preempts state-law tort claims challenging generic product warnings.; Susan B. Anthony List, et al. v. Driehaus, et al., No. 13-193 (S. Ct. 2014 Term): amicus counsel for the Foundation for Individual Rights in Education in case involving the appropriate ripeness standard for free speech pre-enforcement challenges brought under the First Amendment.; Wagner v. Teva Pharms USA., Inc., 840 F.3d 355 (7th Cir. 2016): successfully defended district court's dismissal of state-law tort claims predicated on allegedly inadequate labeling and design on federal preemption grounds.; Brinkley v. PLIVA, Inc ., 772 F.3d 1133 (8th Cir. 2014): successfully defended district court's dismissal of state-law tort strict liability design defect, strict liability failure to warn, negligence, and breach of express and implied warranty claims on federal preemption grounds.; In re Darvocet, Darvon, and Propoxyphene Prods. Liab. Litig ., 756 F.3d 917 (6th Cir. 2014): successfully defended district court's dismissal of multi-district litigation plaintiffs' state-law tort claims on federal preemption grounds.; In re Fosamax (Alendronate Sodium) Prods. Liab. Litig. (No. II), 751 F.3d 150 (3d Cir. 2014): successfully defended district court's dismissal of multi-district litigation plaintiffs' state-law design-defect and other tort claims on grounds of federal preemption.; Drager v. PLIVA USA, Inc., 741 F.3d 470 (4th Cir. 2014): successfully defended district court's holding that plaintiffs' state-law negligence, strict liability, breach of warranty, and misrepresentation and fraud claims all are preempted by federal law.; Abrahamsen v. ConocoPhillips Co., 2014 WL 2884870 (Del. Sup. Ct. May 30, 2014): secured dismissal, as a matter of Delaware forum non conveniens law, of four complaints asserting Delaware personal-injury claims that over one hundred Norwegian workers allegedly incurred while working on oil rigs and platforms in the North Sea.; Wells v. Allergan USA, Inc., et al ., 2014 WL 117773 (D.S.C. Jan. 13, 2014): secured dismissal of various state-law tort claims asserted against Class III medical device manufacturer as preempted by the Medical Device Amendments to the Food, Drug & Cosmetics Act.; Henderson v. Palmer, 730 F.3d 554 (6th Cir. 2013): on behalf of pro bono client, secured reversal of district court's denial of habeas corpus petition, allowing client to assert his claims on the merits in the district court.; Washington v. Medicis Pharms. Corp ., 2013 WL 496063 (S.D. Miss. Feb. 7, 2013): on behalf of manufacturer of generic drug product, secured dismissal of various state-law tort claims premised on innovator liability theory.; Cook v. Rockwell Int'l Corp., 618 F.3d 1127 (10th Cir. 2010): secured reversal of $926 million judgment in favor of plaintiff class in nuclear environmental contamination case on a variety of grounds, including erroneous interpretation of the federal Price-Anderson Act establishing claims for nuclear-related liability, erroneous approach to preemption of state law by federal nuclear safety standards, and erroneous interpretation of the Colorado common law of trespass and nuisance.; United States v. Philip Morris USA, Inc., et al., 566 F.3d 1095 (D.C. Cir. 2009): secured reversal and remand of client-specific rulings made by district court in $280 billion RICO/health care recovery action brought by the Department of Justice.; Secured dismissal of dozens of state and federal cases at the motion-to-dismiss and summary-judgment stages on federal preemption grounds on behalf of Teva Pharmaceuticals, Baxter Healthcare, Ranbaxy Laboratories, and other prescription drug manufacturers.; Counsel for Teva Pharmaceuticals and related entities in nationwide products-liability litigation involving unapproved drugs.; Counsel for Teva Pharmaceuticals and related entities in complex multidistrict commercial litigation involving more than 20 cases brought by state Attorneys General alleging Medicaid/Medicare fraud and unfair competition based on purported inflation of published drug prices (AWP/WAC).; Counsel for Baxter International and Teva Pharmaceuticals in major product-liability litigation involving anesthesia product.; The above representations were handled by Mr. Crisham prior to his joining Greenberg Traurig, LLP.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.